<DOC>
	<DOCNO>NCT00578617</DOCNO>
	<brief_summary>The CABANA pilot study design test hypothesis treatment strategy percutaneous leave atrial catheter ablation purpose elimination atrial fibrillation ( AF ) superior current state-of-the-art therapy either rate control anti-arrhythmic drug reduce AF recurrence 1 year follow-up .</brief_summary>
	<brief_title>Ablation vs Drug Therapy Atrial Fibrillation - Pilot Trial</brief_title>
	<detailed_description>The need trial arise 1 ) rapidly increase number pt &gt; 60 year age AF accompany symptom morbidity , 2 ) failure anti-arrhythmic drug therapy maintain sinus rhythm reduce mortality , 3 ) rapidly increase application radio-frequency catheter ablation without appropriate evidence-based validation , 4 ) expand impact AF health care cost .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Have document AF , warrant active drug ablative treatment Be eligible catheter ablation least 2 sequential antiarrhythmic drug and/or 3 sequential rate control drug Be &gt; 65 yrs age , &lt; 65 yr one follow risk factor stroke : Hypertension , Diabetes , Congestive heart failure ( include systolic diastolic heart failure ) , Prior stroke transient ischemic attack , Left atrium &gt; 4.5 cm , ejection fraction &lt; 35 % echocardiogram , radionuclide evaluation contrast ventriculography Previously fail 2 membrane active antiarrhythmic drug Efficacy failure full dose Amiodarone trial &gt; 12 week duration Any amiodarone therapy past three month Reversible cause AF include thyroid disorder , acute alcohol intoxication , recent major surgical procedure , trauma Lone atrial fibrillation absence risk factor stroke patient &lt; 65 year age Recent cardiac event include myocardial infarction , percutaneous intervention , valve coronary bypass surgery precede 3 month Hypertrophic obstructive cardiomyopathy Class IV angina congestive heart failure Planned heart transplantation Other mandate antiarrhythmic drug therapy Heritable arrhythmia increase risk `` torsade de pointes '' ( specific , rare variety ventricular tachycardia ) class I III drug Prior leave atrial catheter ablation intention treat AF Patients arrhythmia require ablative therapy Prior surgical intervention AF MAZE procedure Prior atrioventricular nodal ablation Medical condition limit expect survival &lt; 1 year Contraindication warfarin anticoagulation Women childbearing potential Participation clinical mortality trial Unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Left Atrial Ablation</keyword>
	<keyword>Pulmonary Vein Isolation</keyword>
	<keyword>Catheter Ablation</keyword>
	<keyword>Antiarrhythmic Drug Therapy</keyword>
</DOC>